Kale, Dinar and Niosi, Jorge
(2017).
| DOI (Digital Object Identifier) Link: | https://doi.org/10.1080/09537325.2016.1274391 |
|---|---|
| Google Scholar: | Look up in Google Scholar |
Abstract
This special issue of Technology Analysis & Strategic Management brings together a collection of recent empirical and conceptual insights on the emergence of biosimilar drugs, focusing on key developments that are significant for industrial dynamics, evolution of regulatory policies and affordable healthcare. Biosimilars are imitative versions of biologicals - a therapeutic drug category comprising large complex molecules. Traditionally, biologicals have been developed to address the most challenging illnesses such as cancer, autoimmune diseases, diabetes, growth hormone deficiency and inflammation. The extraordinary interest in biosimilars is driven by blockbuster biological products going off-patents, and evolving regulatory frameworks are paving the way for their entry into health care markets. This has created a significant opportunity for the pharma-biotech industry and government policy-makers to provide affordable treatments in advanced as well as developing countries. The promise of biosimilars as significant market opportunity is being heralded in an era of growing aging population and increasing healthcare costs.
| Item Type: | Journal Item |
|---|---|
| Copyright Holders: | 2017 Informa UK Limited, trading as Taylor & Francis Group |
| ISSN: | 1465-3990 |
| Extra Information: | Editorial |
| Keywords: | biosimilar; healthcare; industrial capabilities; biotechnology industry; pharmaceutical industry |
| Academic Unit/School: | Faculty of Arts and Social Sciences (FASS) > Politics, Philosophy, Economics, Development, Geography > Development Faculty of Arts and Social Sciences (FASS) > Politics, Philosophy, Economics, Development, Geography Faculty of Arts and Social Sciences (FASS) |
| Research Group: | Innovation, Knowledge & Development research centre (IKD) International Development & Inclusive Innovation Health and Wellbeing PRA (Priority Research Area) Institute for Innovation Generation in the Life Sciences (Innogen) |
| Item ID: | 48632 |
| Depositing User: | Dinar Kale |
| Date Deposited: | 16 Feb 2017 13:54 |
| Last Modified: | 13 Feb 2019 08:30 |
| URI: | http://oro.open.ac.uk/id/eprint/48632 |
| Share this page: |     |
Metrics
Altmetrics from Altmetric | Citations from Dimensions |
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)